ArticleBMC research notes2018
Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: comparison with invasive ductal carcinoma of breast.
Article in BMC research notes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.Discover oncology · 2026Article
- Rare Histological Types of Breast Cancer: A Single-Center Experience.The breast journal · 2025Article
- HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy.Frontiers in immunology · 2025Article
- Promising Response to Neoadjuvant Chemotherapy Plus Immunotherapy in Metaplastic Breast Carcinoma.Breast cancer (Dove Medical Press) · 2025Article
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Article
- Unusual Case of Papillary Carcinoma of the Breast.Cureus · 2024Article
- An overview of invasive micropapillary carcinoma of the breast: past, present, and future.Frontiers in oncology · 2024Review
- Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma.Disease markers · 2024Article
- Invasive micropapillary breast carcinoma: A retrospective study on the clinical imaging features and pathologic findings.Frontiers in surgery · 2022Article
- Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis.Breast cancer (Dove Medical Press) · 2022Review
- Clinicopathological and Radiological Features with Long Term Follow Up of Metaplastic Carcinoma Breast in India.Asian Pacific journal of cancer prevention : APJCP · 2021Observational
- HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.Archives of pathology & laboratory medicine · 2021Article
- Article
- Article
- Article
- Article
- Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma.Cureus · 2021Article
- Invasive Papillary Carcinoma of the Breast: Clinicopathological Features and Hormone Receptor Profile.Cureus · 2021Article
- Encapsulated Papillary Carcinoma of Breast: Clinicopathological Features and Prognostic Parameters.Cureus · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to determine the frequency of metaplastic breast carcinoma and invasive micropapillary carcinoma in our population and also to compare the clinico-pathologic features of metaplastic breast carcinoma and invasive micropapillary carcinoma with invasive ductal carcinoma, not otherwise specified (IDC, NOS).
results86.9% of the cases were identified as ductal carcinoma, NOS, while 2.2% were metaplastic and 0.76% cases were micropapillary carcinoma. Metaplastic carcinomas were found to be of higher grade as compared to IDC, NOS as 81% of metaplastic carcinoma were grade III compared to 35% IDC, NOS. 79% of metaplastic carcinoma were ER negative and 86% were PR negative, respectively as compared to ductal carcinoma NOS, which were 40% ER negative and 54% were PR. Similarly, 86.7% micropapillary cancers were ER positive and 73.3% were PR positive. Moreover, 66.7% micropapillary carcinoma showed nodal metastasis and 77.8% showed lymphovascular invasion, which was significantly higher than that of IDC, NOS micropapillary and metaplastic carcinomas accounts for less than 2 and 1% of the breast cancer burden in our population and highly correlates with poor prognosis parameters therefore, require more intensive management in our population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.